Literature DB >> 19775911

Goals of stability evaluation throughout the vaccine life cycle.

Philip R Krause1.   

Abstract

Stability studies play a critical role in assuring product quality at all points in the vaccine life cycle. At and after licensure, stability studies on quality attributes (including potency) provide a critical link between marketed and clinically evaluated vaccine product, addressing important regulatory concerns by assuring that product quality is maintained throughout the dating period. During development, stability studies are done to assure product quality and to obtain the data needed to support licensure. Stability studies may also be performed after licensure to assure that product continues to perform as it did pre-licensure, as well as to evaluate the effect on product quality of deliberately introduced manufacturing changes. At each phase in the product life cycle, it is important to consider the goals of stability evaluation and to perform appropriate statistical analyses in order to assure and reach appropriate conclusions about product quality.

Mesh:

Substances:

Year:  2009        PMID: 19775911     DOI: 10.1016/j.biologicals.2009.08.015

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  4 in total

1.  Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team.

Authors:  Lindsay E King; Esme Farley; Mami Imazato; Jeannine Keefe; Masood Khan; Mark Ma; K Susanne Pihl; Priya Sriraman
Journal:  AAPS J       Date:  2014-04-01       Impact factor: 4.009

2.  Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.

Authors:  Felix Geeraedts; Vinay Saluja; Wouter ter Veer; Jean-Pierre Amorij; Henderik W Frijlink; Jan Wilschut; Wouter L J Hinrichs; Anke Huckriede
Journal:  AAPS J       Date:  2010-03-02       Impact factor: 4.009

3.  Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study.

Authors: 
Journal:  Hum Vaccin Immunother       Date:  2018-08-29       Impact factor: 3.452

4.  Potency testing for a recombinant protein vaccine early in clinical development: Lessons from the Schistosoma mansoni Tetraspanin 2 vaccine.

Authors:  Guangzhao Li; Lara Hoeweler; Brian Keegan; Jin Peng; Larissa Scholte; Peter Hotez; Maria Elena Bottazzi; David Diemert; Jeffrey Bethony
Journal:  Vaccine X       Date:  2021-06-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.